Loading stock…

Iovance Biotherapeutics, Inc. (IOVA) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Iovance Biotherapeutics, Inc.

IOVAMarket cap $5.87BPrice $13.0

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops cell therapies that reprogram a patient's own immune cells to hunt down cancer. Its melanoma treatment became the first FDA-approved TIL therapy in history, opening a new frontier beyond chemo and checkpoint inhibitors for solid tumors.

In Bastion Portfolios?

52W Return+494%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)+56%10

Rev CAGR (3y)+47%10

Rev CAGR (5y)+37%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+30%5

Quality

Margins

EBIT Margin-91%1

Net Income Margin-89%1

Free Cash Flow Margin-91%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-40%1

ROA-32%1

Earnings Stabilityna–

GEAR+VERY WEAK10

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)591

P/BV8.02

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-5.0%1

Dividend Yieldna–

Momentum

Short term

1 month return+47%10

3 month return+198%10

YTD return+375%10

Mid term

Price vs 52wHigh85%6

1 year return+494%10

Long term

3 year return+221%9

5 year return-51%1

Risk Shield

Price Risk

Beta1.42

Volatility98%1

Free Cash Flow

Free Cash Flow Margin-91%1

Free Cash Flow Yield-5.0%1

Quality

ROCE-37%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

IOVAIovance Biotherapeutics

Revenue FY25$264M

GROWTH RATING↗

STRONG79 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+56%10

Revenue, next 3Y, CAGR+47%10

Revenue, next 5Y, CAGR+37%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 79% of companies worldwide.

Revenue is set to grow 47%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 47%/yr from here.

The runway holds up: revenue is set to grow 37%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG83 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+47%10

3-month return+198%10

YTD return+375%10

MID & LONG-TERM▾SCORE

% of 52-week high85%6

1-year return+494%10

3-year return+221%9

5-year return-51%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 494% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+47%), over three months (+198%) and so far this year (+375%).

WATCH

Average long-term results. Multi-year returns are middling (+221% over three years and -51% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Iovance Biotherapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

IOVAIovance Biotherapeutics

Revenue FY25$264M

GROWTH RATING↗

STRONG79 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Y+56%10

Revenue, next 3Y, CAGR+47%10

Revenue, next 5Y, CAGR+37%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 79% of companies worldwide.

Revenue is set to grow 47%/yr over the next 3 years, ahead of most of the market.10/10

Revenue held flat over the last 3 years and is set to grow 47%/yr from here.

The runway holds up: revenue is set to grow 37%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG83 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+47%10

3-month return+198%10

YTD return+375%10

MID & LONG-TERM▾SCORE

% of 52-week high85%6

1-year return+494%10

3-year return+221%9

5-year return-51%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 494% over the past year, but 15% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+47%), over three months (+198%) and so far this year (+375%).

WATCH

Average long-term results. Multi-year returns are middling (+221% over three years and -51% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Iovance Biotherapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community